Related Experiment Video
Updated: Aug 10, 2025
Simultaneous Quantification of T-Cell Receptor Excision Circles TRECs and K-Deleting Recombination Excision Circles KRECs by Real-time PCR
Published on: December 6, 2014
Predictors of Remission in Severe Childhood Immune Thrombocytopenia
Chao-Neng Cheng1,2, Yuan-Ning Yang1, Yun-Hsuan Yeh1
1Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng-Kung University, Tainan 704302, Taiwan.
Insights
Childhood immune thrombocytopenia (ITP) remission is predicted by diagnosis before age 10, abrupt symptom onset, and rapid platelet recovery. These factors aid in guiding families on the likely course of this common childhood bleeding disorder.
Area of Science:
- Pediatric Hematology
- Immunology
- Clinical Medicine
Background:
- Childhood immune thrombocytopenia (ITP) is the most frequent bleeding disorder in children, with 3-5% facing severe bleeding risks.
- While often self-limited, severe ITP requires monitoring, and 20% may develop chronic forms.
- Predicting early remission in severe ITP is crucial for family guidance and management.
Purpose of the Study:
- To identify shared clinical factors predicting disease remission at 3, 6, and 12 months post-diagnosis in children with severe ITP.
- To analyze associations between initial diagnostic factors and remission definitions at various timepoints.
Main Methods:
- Retrospective analysis of 497 children diagnosed with severe ITP (platelet count < 30 × 10^9/L) between 1988 and 2019.
- Inclusion criteria: hospitalized children under 18, severe ITP at diagnosis, and follow-up data within 12 months.
- Exclusion criteria: mild ITP at diagnosis or loss to follow-up within 3 months.
Main Results:
- 73.2% achieved remission by 3 months, 8.1% between 6-12 months, and 20.9% developed chronic ITP.
- Significant predictors for remission across all timepoints included: pre-adolescent age (<10 years), abrupt onset (≤2 weeks), and rapid platelet recovery (>100 × 10^9/L at 1 month).
- Viral serology or recent vaccination showed a trend towards delayed remission.
Conclusions:
- Pre-adolescent age at diagnosis, abrupt symptom onset, and rapid early recovery are favorable predictors for childhood ITP remission.
- These factors can help anticipate disease course and inform family counseling for pediatric ITP cases.
Abstract:
Childhood immune thrombocytopenia (ITP; platelet count < 100 × 109/L) is the most common bleeding disorder in children. A total of 3-5% of children with ITP face a greater risk of bleeding, resulting in significant morbidity and mortality. Childhood ITP is often benign and self-limited; however, children with severe ITP (platelet count < 30 × 109/L) require investigation and monitoring. In addition, 20% of ITP patients may not go into remission (platelet counts < 100 × 109/L by 12 months after diagnosis) and may develop chronic ITP. The early identifying predictors associated with the resolution of severe ITP at the time of diagnosis may be helpful for family guidance. However, there is still controversy about the associations between the clinical factors at the time of initial diagnosis and the definitions of disease remission assessed at different timepoints after diagnosis. This retrospective study aimed to analyze the shared clinical factors among the disease remission definitions at three arbitrarily set timepoints-3, 6, and 12 months after diagnosis. This study retrieved records for hospitalized children aged under 18 years and diagnosed with ITP from the hospital registry in a tertiary university hospital. Clinical variables were recorded by reviewing the medical records with structured data entry for ITP admission. The serial follow-up platelet counts within 12 months after diagnosis were recorded. The times of ITP remission were identified by experienced pediatric hematologists. Patients with mild-form ITP (platelet counts ≥ 30 × 109/L) at diagnosis or who were lost to follow-up within 3 months were excluded. From 1988 to 2019, 546 children were enrolled, and a total of 497 children with severe ITP were included in the further analysis. In total, one (0.2%) died of an intracranial hemorrhage, 363 (73.2%) children went into remission at 3 months, 40 (8.1%) went into remission between 6 and 12 months, and 104 (20.9%) developed chronic ITP. The shared significant predictors for remission by the third, sixth, and twelfth months included pre-adolescent age (<10 years) at diagnosis, abrupt onset (duration of symptoms prior to admission ≤ 2 weeks), and speedy recovery (platelet count > 100 × 109/L at 1 month post diagnosis). ITP patients with positive viral serology tests or vaccination within 4 weeks had trends of delayed remission. In conclusion, diagnosis before preadolescent age, abrupt onset, and speedy recovery may share favorable factors for the remission of childhood ITP assessed at different timepoints.
